Maegim한국어

대봉엘에스

078140KOSDAQSector: Pharma & Biotech
₩7,540▼ 0.40%Market cap ₩83.6BAs of Jul 21, 2026 close · updated once daily
A
Grade A68.6 ptsTop 14% of 2,523 stocks
Financial strength
70.0
Growth momentum
42.4
Price attractiveness
85.6

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

70.0
How much debt does it carry relative to equity?
Debt-to-equity ratio
51.5%
✓ Above median · Top 49.4% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
544.3%
✓ Above median · Top 25% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
7.2%
✓ Above median · Top 24.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
7.1%
✓ Above median · Top 21.7% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

42.4
How much did revenue grow in a year?
Revenue growth (YoY)
8.6%
✓ Above median · Top 42.2% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
3.0%
✗ Below median · Top 57.4% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-19.0%
✗ Below median · Top 72.1% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-10.3%
✗ Below median · Top 58.9% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

85.6
Is the price expensive relative to earnings?
P/E (price-to-earnings)
8.3x
✓ Above median · Top 10.8% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.59x
✓ Above median · Top 18.1% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15